GlassScriptPhysician profile
Diana Padget
NPI 1528559978
$1,955.61
in general payments reported to CMS, 2019-2025
23 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $230 · 2021: $27.00 · 2022: $153 · 2023: $453 · 2024: $530 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $404.94 | 2022-2025 | Lifevest |
| Vifor Pharma, INC. | $238.18 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $237.50 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $149.99 | 2023 | Xarelto |
| Medtronic, INC. | $134.10 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $129.92 | 2023-2024 | Verquvo |
| Novo Nordisk INC | $70.47 | 2024-2025 | Wegovy |
| Scpharmaceuticals INC. | $69.61 | 2024-2025 | |
| Pfizer INC. | $68.77 | 2023-2024 | |
| Amgen INC. | $58.20 | 2024-2025 | Repatha |
| Lexicon Pharmaceuticals, INC. | $55.48 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $53.87 | 2024 | Arcalyst |
| Abiomed | $44.38 | 2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $35.29 | 2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $32.23 | 2025 | Wainua |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $31.40 | 2024 | Amvuttra, Onpattro |
| Bard Peripheral Vascular, INC. | $28.24 | 2024 | Halo One Thin-Walled Guiding Sheath |
| Novartis Pharmaceuticals Corporation | $24.89 | 2024 | |
| Abbott Laboratories | $20.26 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.53 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.69 | 2024 | Jardiance |
| Lantheus Medical Imaging, INC. | $16.39 | 2022 | |
| Lilly USA, LLC | $15.28 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Padget listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.